MENLO PARK, Calif. – Pacific Biosciences of California, Inc., provider of

Single Molecule Real Time (SMRT®) sequencing products, today announced that DNA Link, Inc.

is the first commercial service provider for PacBio®RS sequencing in Asia and the first PacBio

RS installation in Korea. The deal was brokered by the company’s new distributor for Korea,

MDxK (Molecular Diagnostics Korea), Inc.

“We’re pleased to add the PacBio platform to our services portfolio,” said Dr. Jong E. Lee, CEO

of DNA Link. “Single Molecule Real-Time Sequencing Technology will open up a new era of

sequencing applications. We expect that it will help to uncover the mysteries of nature.”

Ram Laxman, Ph.D., Vice President of Sales for Asia at Pacific Biosciences commented: “We are

excited to expand our business in Asia and to have our first service provider in the region. We

trust their expertise to help handle many of the requests for single molecule, extremely long read

sequencing services from the Asian research community.”

The PacBio RS is a revolutionary DNA sequencing system that rapidly reveals new biological

insights by incorporating novel, single molecule sequencing techniques, advanced analytics, and

long readlengths. The PacBio RS is uniquely suited for genetic variant validation, providing

scientists with a high level of certainty due to high single molecule consensus accuracy and the

very long readlengths. The fast time to result enables researchers to complete validation

experiments rapidly, an important benefit for medical and clinical research. The system is also

ideal for cost effectively finishing genomes and for providing de novo assemblies of microbial

genomes such as infectious pathogens with strain-level resolution.

About DNA Link, Inc.

Established in March 2000, DNA Link, Inc. is a leading contract research service provider of

genomics studies. The company focuses on the study of genetic variations, especially on Single

Nucleotide Polymorphisms (SNPs) and the development of new drug targets. SNPs are the most

common form of genetic variation and are expected to play an essential role in the future of drug

development, diagnostics and other life science applications. As a genomics-based biotechnology

company, DNA Link, Inc. has a complete genotyping solution and large-scale resource of clinical

research. For more information visit www.dnalink.com.

About Pacific Biosciences, Inc.

Pacific Biosciences’ mission is to transform the way humankind acquires, processes and

interprets data from living systems through the design, development and commercialization of

innovative tools for biological research. The company has developed a novel approach to

studying the synthesis and regulation of DNA, RNA and proteins. Combining recent advances in

nanofabrication, biochemistry, molecular biology, surface chemistry and optics, Pacific

Biosciences has created a powerful technology platform called single molecule, real-time, or

SMRT,technology. SMRT technology enables real-time analysis of biomolecules with single

molecule resolution, which has the potential to transform the understanding of biological systems

by providing a window into these systems that has not previously been open for scientific study.

For more information about Pacific Biosciences, please visit www.pacificbiosciences.com. You

can also follow the company on Twitter: www.twitter.com/pacbio.